KYMR Kymera Therapeutics, Inc.
Nasdaq · SEC CIK 1815442 · EDGAR
- Bought, last 12 months
- $172.50M 1 purchases by 1 insiders
- Sold, last 12 months
- $475.84M 50 sales by 11 insiders
- Filings on record
- 212 since 2021-07-06, latest 2026-09-04 18:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Booth Bruce | Dir | — | $226.03M |
| BVF PARTNERS L P/IL | Dir, See Remarks, Footnotes | — | $173.67M |
| BAKER FELIX | Dir, 10% | $172.50M | — |
| Mainolfi Nello | CEO, Dir | — | $33.41M |
| Chadwick Jeremy G | COO | — | $15.60M |
| Jacobs Bruce N. | CFO | — | $9.96M |
| Gollob Jared | Chief Medical Off | — | $9.13M |
| Esposito Pamela | Dir | — | $3.05M |
| Goodman Noah | Chief Business Off | — | $2.22M |
| Ridloff Elena | Dir | — | $1.29M |
Transactions 233
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-01-26 | 2022-01-24 | KYMR | Biotechnology Value Trading Fund OS LP | See Explanation of Responses | P - Purchase | $37.76 | +272.8K | 1.34M | +25% | +$10.30M |
| DM | 2022-01-14 | 2022-01-12 | KYMR | Jacobs Bruce N. | CFO | S - Sale+OE | $51.84 | -15.0K | 26.1K | -37% | -$777.7K |
| D | 2022-01-14 | 2022-01-12 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +15.0K | 32.5K | +86% | +$31.2K |
| D | 2022-01-14 | 2022-01-14 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 27.5K | +57% | +$20.8K |
| D | 2022-01-14 | 2022-01-14 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +10.0K | 482.2K | +2% | +$20.8K |
| DM | 2022-01-12 | 2022-01-10+ | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +48.0K | 489.1K | +11% | +$99.8K |
| DM | 2022-01-12 | 2022-01-10+ | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $53.31 | -48.0K | 472.2K | -9% | -$2.56M |
| D | 2021-12-16 | 2021-12-16 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +8,000 | 472.2K | +2% | +$16.6K |
| D | 2021-12-03 | 2021-12-03 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 27.5K | +57% | +$20.8K |
| DM | 2021-12-03 | 2021-12-03 | KYMR | Jacobs Bruce N. | CFO | S - Sale+OE | $53.56 | -10.0K | 19.8K | -34% | -$535.6K |
| D | 2021-11-23 | 2021-11-23 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 17.3K | +138% | +$20.8K |
| DM | 2021-11-02 | 2021-11-01+ | KYMR | Gollob Jared | Chief Medical Off | S - Sale+OE | $62.16 | -57.5K | 44.6K | -56% | -$3.57M |
| DM | 2021-11-02 | 2021-11-01+ | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $1.69 | +39.6K | 62.5K | +173% | +$67.0K |
| DM | 2021-10-12 | 2021-10-08+ | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $56.34 | -48.0K | 475.1K | -9% | -$2.70M |
| DM | 2021-10-12 | 2021-10-08+ | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +48.0K | 505.7K | +10% | +$99.8K |
| DM | 2021-09-03 | 2021-09-03 | KYMR | Jacobs Bruce N. | CFO | S - Sale+OE | $60.12 | -10.0K | 7,256 | -58% | -$601.2K |
| D | 2021-09-03 | 2021-09-03 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | -10.0K | 17.3K | -37% | -$20.8K |
| D | 2021-08-27 | 2021-08-27 | KYMR | Chesworth Richard | CSO | M - OptEx | $20.00 | +33.8K | 33.8K | New | +$675.6K |
| D | 2021-08-27 | 2021-08-27 | KYMR | Chesworth Richard | CSO | S - Sale+OE | $60.12 | -33.8K | 0 | -100% | -$2.03M |
| DM | 2021-08-19 | 2021-08-17 | KYMR | Chesworth Richard | CSO | S - Sale+OE | $50.37 | -54.0K | 45.2K | -54% | -$2.72M |
| D | 2021-08-19 | 2021-08-17 | KYMR | Chesworth Richard | CSO | M - OptEx | $20.00 | +54.0K | 54.0K | New | +$1.08M |
| D | 2021-08-19 | 2021-08-19 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +12.0K | 464.2K | +3% | +$25.0K |
| 2021-08-12 | 2021-08-11 | KYMR | Atlas Venture Associates X, LLC | 10% | S - Sale | $61.00 | -242.1K | 0 | -100% | -$14.77M | |
| I | 2021-08-12 | 2021-08-11 | KYMR | Booth Bruce | Dir | S - Sale | $61.00 | -242.1K | 0 | -100% | -$14.77M |
| DM | 2021-08-05 | 2021-08-03+ | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $60.06 | -6,706 | 452.2K | -1% | -$402.8K |
| DM | 2021-08-05 | 2021-08-03+ | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +6,706 | 457.9K | +1% | +$13.9K |
| DM | 2021-08-02 | 2021-07-29+ | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $60.25 | -30.4K | 452.2K | -6% | -$1.83M |
| DM | 2021-08-02 | 2021-07-29+ | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +30.4K | 475.7K | +7% | +$63.3K |
| DM | 2021-07-28 | 2021-07-26+ | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +12.9K | 456.1K | +3% | +$26.8K |
| DM | 2021-07-28 | 2021-07-26+ | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $60.15 | -12.9K | 452.2K | -3% | -$774.7K |
| DM | 2021-07-09 | 2021-07-08 | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $49.70 | -48.0K | 452.2K | -10% | -$2.39M |
| D | 2021-07-09 | 2021-07-08 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +48.0K | 500.2K | +11% | +$99.8K |
| M | 2021-07-06 | 2021-07-01 | KYMR | BIOTECHNOLOGY VALUE FUND L P | See Explanation of Responses | P - Purchase | $47.00 | +544.2K | 208.5K | New | +$25.58M |
Purchase Sale Sale after option exercise All abbreviations